Supplementary data

Figure 1. Consort diagram of the study


Supplementary data

Figure 1. Consort diagram of the study

All patients, N= 805

Exclusion, N= 521

- EGFR mutation unknown/negative, n= 402

- Medical files loss/inadequate data, n= 78

- Uncommon mutation, n= 22

- Received treatment after 2019, n= 19

Enrolled patients, n= 284

Table 1. Number of patients enrolled to the study classified by medical center

Study site	Province	Total N=284 n (%)
Rajavithi Hospital	Bangkok	56 (19.7)
Taksin Hospital	Bangkok	33 (11.6)
Police General Hospital	Bangkok	31 (10.9)
Chulaborn Hospital	Bangkok	22 (7.7)
Chonburi Cancer Hospital	Chonburi	51 (18.0)
Buddasothorn Hospital	Chacheongsao	32 (11.3)
Sawanpracharak Hospital	Nakornsawan	19 (6.7)
Nakornping Hospital	Chiangmai	13 (4.6)
Surin Hospital	Surin	18 (6.3)
Udonthani Cancer Hospital	Udonthani	9 (3.2)

Table 2. Clinical characteristics comparing between chemotherapy 1L and EGFR-TKI 1L

Factors	Chemotherapy N=120	EGFR-TKI N=162	P
Age			0.002
Median (min-max), years	61 (36-86)	65 (33-90)	
Sex			0.770
Female	78 (65.0)	108 (66.7)	
Male	42 (35.0)	54 (33.3)	
Smoking status			0.756
Never/unknown	92 (78.0)	128 (79.5)	
Smoking	26 (22.0)	33 (20.5)	
Health fund			0.315
UC/SSS	72 (60.0)	106 (65.8)	
GSEO/Self pay	48 (40.0)	55 (34.2)	
ECOG-PS			0.518
0-2	98 (55.8)	137 (54.9)	
3-4/unknown	22 (25.8)	25 (29.6)	
Stage			0.399
3B and 4	113 (94.2)	156 (96.3)	
Recurrence	7 (5.8)	6 (3.7)	
Tumor pathology			0.544
Adenocarcinoma	112 (93.3)	153 (95.0)	
Others	8 (6.7)	8 (5.0)	
EGFR mutation			0.014
Exon 19 deletion	83 (69.2)	88 (54.7)	
L858R mutation	37 (30.8)	73 (45.3)	

Table 3. Adverse events of erlotinib and gefitinib

Adverse events	Erlotinib				Gefitinib			
	Grading (%)				Grading (%)			
	Any	1	2	≥3	Any	1	2	≥3
Rash	71.7	50.0	13.0	8.7	54.5	40.7	9.7	4.1
Paronychiae	46.1	34.6	3.8	7.7	38.4	30.8	4.4	3.3
Stomatitis	34.6	34.6	0	0	19.8	15.1	4.7	0
Diarrhea	33.3	31.1	2.2	0	21.0	14.7	3.5	2.8
Hepatitis	2.2	0	2.2	0	12.6	7.7	2.1	2.8